In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biacore International AB

Division of General Electric Co.
www.biacore.com

Latest From Biacore International AB

Siemens--Stealing GE's Thunder

Siemens AG continues to assemble the pieces necessary to create a one-stop-shop for medical testing. With its $7 billion take-out of Dade Behring Holdings Inc., the German industrial giant ups the acquisition ante for in vitro diagnostic companies. Rival GE may have to play catch-up if it wants to maintain its leadership position in medical testing.
Medical Device Business Strategies

Siemens acquires Bayer Diagnostics, Creates Integrated Diagnostics Powerhouse

Following upon its announcement in May that it would pay $1.86 billion for Diagnostics Products, to bring an immunodiagnostics business in-house, Siemens announced in June that it will acquire Bayer Diagnostics for approximately €4.2 billion or $5.26 billion. Siemens thus catapults itself to the number two spot in the immunodiagnostics segment of IVD, after Roche, and by its calculations, now plays a close third to Abbott Laboratories in the overall in vitro diagnostics market.
Medical Device Research and Development Strategies

GPC Looks to Nasdaq for the Best of Both Worlds

A late-June listing may help Germany's GPC Biotech AG attract investor interest and it certainly reinforces the firm's increasing Americanization. Yet the performance of lead candidate satraplatin remains the strongest determinant of GPC's valuation and near-term success.
BioPharmaceutical Strategy

The US: To Go, or Not to Go?

Whether or not European biotechs should establish operations in the US may seem like a no brainer: it's the biggest drugs market, with more potential partners, better funding, more promising exits for investors and a more experienced management pool than Europe. But getting there-and getting noticed-isn't easy. And since most executives agree that going to the US half-heartedly isn't worthwhile, Europe's biotechs need to think hard about when and whether they're ready to go. For a minority, setting up in the US may not be the right solution-for now.
Europe United States
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
      • Antibodies
    • Nanotechnology, Chips, etc.
  • In Vitro Diagnostics
    • Biosensors
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Sweden
  • Parent & Subsidiaries
  • General Electric Co.
  • Senior Management
  • Lars-Olov Forslund, CFO
    E. W Radany, VP, US Sales & Mktg.
    Terry Pizzie, VP, Commercial Oper.
  • Contact Info
  • Biacore International AB
    Phone: (46) 18 675700
    Rapsgatan 7
    Uppsala, V7 S-754 5
    Sweden
Advertisement
Advertisement
UsernamePublicRestriction

Register